CHMP recommend market authorisation for generic fampridine (fampridine accord)

Studies have demonstrated the satisfactory quality of fampridine Accord and its bioequivalence to the reference product Fampyra. It is intended to be licenced for the improvement of walking in adult patients with multiple sclerosis with walking disability.

SPS commentary:

he UK patent expiry for Fampyra is July 2026.


European Medicines Agency